These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 18023222)

  • 1. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease.
    Auray-Blais C; Cyr D; Ntwari A; West ML; Cox-Brinkman J; Bichet DG; Germain DP; Laframboise R; Melançon SB; Stockley T; Clarke JT; Drouin R
    Mol Genet Metab; 2008 Mar; 93(3):331-40. PubMed ID: 18023222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry.
    Auray-Blais C; Blais CM; Ramaswami U; Boutin M; Germain DP; Dyack S; Bodamer O; Pintos-Morell G; Clarke JT; Bichet DG; Warnock DG; Echevarria L; West ML; Lavoie P
    Clin Chim Acta; 2015 Jan; 438():195-204. PubMed ID: 25149322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients.
    Abaoui M; Boutin M; Lavoie P; Auray-Blais C
    Clin Chim Acta; 2016 Jan; 452():191-8. PubMed ID: 26593248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fabry disease urinary globotriaosylceramide/creatinine biomarker evaluation by liquid chromatography-tandem mass spectrometry in healthy infants from birth to 6 months.
    Barr C; Clarke JT; Ntwari A; Drouin R; Auray-Blais C
    Mol Genet Metab; 2009 Aug; 97(4):278-83. PubMed ID: 19464216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
    Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
    Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring.
    Rozenfeld PA; De Francesco NP; Borrajo GJ; Ceci R; Fossati CA
    Clin Chim Acta; 2009 May; 403(1-2):194-7. PubMed ID: 19268437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevation of urinary globotriaosylceramide (GL3) in infants with Fabry disease.
    Chien YH; Olivova P; Zhang XK; Chiang SC; Lee NC; Keutzer J; Hwu WL
    Mol Genet Metab; 2011 Jan; 102(1):57-60. PubMed ID: 20864368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Separation and Analysis of Lactosylceramide, Galabiosylceramide, and Globotriaosylceramide by LC-MS/MS in Urine of Fabry Disease Patients.
    Boutin M; Menkovic I; Martineau T; Vaillancourt-Lavigueur V; Toupin A; Auray-Blais C
    Anal Chem; 2017 Dec; 89(24):13382-13390. PubMed ID: 29099167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of globotriaosylceramide in plasma and urine by mass spectrometry.
    Krüger R; Bruns K; Grünhage S; Rossmann H; Reinke J; Beck M; Lackner KJ
    Clin Chem Lab Med; 2010 Feb; 48(2):189-98. PubMed ID: 19958207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is globotriaosylceramide a useful biomarker in Fabry disease?
    Young E; Mills K; Morris P; Vellodi A; Lee P; Waldek S; Winchester B
    Acta Paediatr Suppl; 2005 Mar; 94(447):51-4; discussion 37-8. PubMed ID: 15895713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Risk Screening of Fabry Disease: Analysis of Fifteen Urinary Methylated and Non-Methylated Gb
    Abaoui M; Boutin M; Lavoie P; Auray-Blais C
    Curr Protoc Hum Genet; 2016 Oct; 91():17.24.1-17.24.11. PubMed ID: 27727434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of death in heart disease is associated with elevated urinary globotriaosylceramide.
    Schiffmann R; Forni S; Swift C; Brignol N; Wu X; Lockhart DJ; Blankenship D; Wang X; Grayburn PA; Taylor MR; Lowes BD; Fuller M; Benjamin ER; Sweetman L
    J Am Heart Assoc; 2014 Feb; 3(1):e000394. PubMed ID: 24496231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome.
    Rombach SM; Aerts JM; Poorthuis BJ; Groener JE; Donker-Koopman W; Hendriks E; Mirzaian M; Kuiper S; Wijburg FA; Hollak CE; Linthorst GE
    PLoS One; 2012; 7(10):e47805. PubMed ID: 23094092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A).
    Liao HC; Huang YH; Chen YJ; Kao SM; Lin HY; Huang CK; Liu HC; Hsu TR; Lin SP; Yang CF; Fann CS; Chiu PC; Hsieh KS; Fu YC; Ke YY; Lin CY; Tsai FJ; Wang CH; Chao MC; Yu WC; Chiang CC; Niu DM
    Clin Chim Acta; 2013 Nov; 426():114-20. PubMed ID: 24055776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
    Sueoka H; Aoki M; Tsukimura T; Togawa T; Sakuraba H
    PLoS One; 2015; 10(12):e0144958. PubMed ID: 26661087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma.
    Ferreira S; Auray-Blais C; Boutin M; Lavoie P; Nunes JP; Martins E; Garman S; Oliveira JP
    Clin Chim Acta; 2015 Jul; 447():96-104. PubMed ID: 26070511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid quantitation of globotriaosylceramide in human plasma and urine: a potential application for monitoring enzyme replacement therapy in Anderson-Fabry disease.
    Boscaro F; Pieraccini G; la Marca G; Bartolucci G; Luceri C; Luceri F; Moneti G
    Rapid Commun Mass Spectrom; 2002; 16(16):1507-14. PubMed ID: 12203240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Globotriaosylceramide (Gb
    Boutin M; Maranda B; Waters PJ
    Curr Protoc; 2024 Jun; 4(6):e1087. PubMed ID: 38896100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interfering parameters in the determination of urinary globotriaosylceramide (Gb3) in patients with chronic kidney disease.
    Gaggl M; Hofer M; Weidner S; Kleinert J; Fauler G; Wallner M; Kotanko P; Paschke E; Sunder-Plassmann G
    J Nephrol; 2015 Dec; 28(6):679-89. PubMed ID: 25857295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young.
    De Brabander I; Yperzeele L; Ceuterick-De Groote C; Brouns R; Baker R; Belachew S; Delbecq J; De Keulenaer G; Dethy S; Eyskens F; Fumal A; Hemelsoet D; Hughes D; Jeangette S; Nuytten D; Redondo P; Sadzot B; Sindic C; Sheorajpanday R; Thijs V; Van Broeckhoven C; De Deyn PP
    Clin Neurol Neurosurg; 2013 Jul; 115(7):1088-93. PubMed ID: 23219219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.